Issue Type: R&D Investment Prioritizes Profitability Over Public Health and Innovation

in challenge narrative

  • Remdesivir Less Expensive for “Government Programs”? Not So Fast.

    Remdesivir Less Expensive for “Government Programs”? Not So Fast.

  • R&D Costs Do Not Explain Elevated U.S. Drug Prices

  • Targeted Drugs for Metastatic Renal Cell Carcinoma